A four-week trial gave 31 frail older adults a daily fiber supplement (low methoxy pectin) or a matched placebo. The fiber group improved more on a leg strength test and had bigger drops in anxiety and depression, tracking with a rise in one gut bacterium, Coprococcus comes. The catch: the inflammation markers the trial was built to test showed no real difference between groups.

TL;DR: A daily fiber supplement eased anxiety and boosted leg strength in frail seniors, tied to a shift in one gut bacterium, but never touched the inflammation markers the study targeted.

ABSTRACT

The human gut hosts approximately 38 trillion bacteria, representing 400 to 500 species. Gut bacteria are in constant communication with the central nervous system (CNS) via the enteric nervous system (ENS), the peripheral nervous system (PNS), the autonomic nervous system (ANS), the immune system, the enteroendocrine system (EES), and the vagus nerve (VN). Short-chain fatty acids (SCFAs), especially butyrate, strengthen the blood-brain barrier (BBB) and modulate inflammatory signaling, thereby affecting brain function and cognitive performance. Acetate enhances the synthesis of lipid-rich myelin that protects neurons. Signaling molecules that cross the gut wall may optimize synaptic signaling in the frontal cortex. Bacterial metabolites that stimulate inflammatory responses activate the hypothalamic-pituitary-adrenal (HPA) axis, thereby increasing glucocorticoid production. This may reduce activity in the prefrontal cortex and suppress higher-order thinking and decision-making. We discuss how signaling molecules produced by gut bacteria influence the limbic system (thalamus, amygdala, hypothalamus, and hippocampus), primarily involved in emotions, memory, and motivation. The HPA axis and the gut microbiota–oligodendrocyte axis (GMOA) are discussed in more detail. We ask whether interactions between signaling molecules produced by gut bacteria and the limbic system can affect human intelligence, cognition, consciousness, and decision-making, coordinated by the cerebrum (cerebral cortex), prefrontal cortex, and parietal lobe.

A review of small intestinal bacterial overgrowth (SIBO) research points to a retrospective study that compared patients tested for suspected SIBO who had used probiotics in the past month with those who hadn't. Recent probiotic users were far more likely to test positive for methane driven bacterial overgrowth than non users, 93.6% versus 65.7%, and the gap held up as independent of other factors. That result comes from a single retrospective study, so it shows a link, not proof that probiotics themselves cause the problem.

TL;DR: One retrospective study found recent probiotic users tested positive for methane linked SIBO far more often than non users, 93.6% vs 65.7%, though it's only an association.

Researchers tracked about 13,700 Chinese adults over nine years, comparing those with and without gastrointestinal disease or heart disease at the start. People with GI disease were 44% more likely to later develop heart disease, and the reverse held too, partly explained by depression. It's observational, so it can't prove one condition causes the other.

TL;DR: Gut disease and heart disease each predicted the other's onset years later in a large cohort, partly through depression, but causation isn't proven.

A review pooled nine small studies comparing gut bacteria in adults with mild cognitive impairment (431 people) to healthy controls (586). Across them, impairment tracked with fewer SCFA-making bacteria like Ruminococcus and Lachnospira and more inflammatory Bacteroides; in one study, fecal bacteria alone correctly flagged 93% of cases. But the studies are small and cross-sectional, and some microbes, like Prevotella, swing in opposite directions between populations.

TL;DR: Gut bacteria shifts track with mild cognitive impairment and can flag it early, but the evidence is too thin to call it diagnostic.

Researchers swabbed tongue coating from 62 older adults, 31 with Alzheimer's and 31 without, then ran bacterial DNA and metabolite tests. The Alzheimer's group had a different bacterial mix and dozens of altered metabolites, with one fat-metabolism pathway standing out as most disrupted, a pattern also seen in their spinal fluid. It's a small, one-hospital study, so it shows a link, not proof the bacteria cause the disease.

TL;DR: Alzheimer's patients showed a distinct tongue bacteria and fat-metabolism signature also found in spinal fluid, but it's a link, not proof of cause.

Researchers compared gut bacteria and genetic ancestry in 441 adults to see which better predicts heart and metabolic risk, like blood pressure, insulin, and body fat. Gut bacteria beat ancestry by a wide margin, 0.05 versus just 0.01, with Akkermansia muciniphila linked to lower risk and E. coli to higher risk. It's a cross-sectional (one-time) snapshot, so it shows a link, not proof the bacteria cause the risk.

TL;DR: Gut bacteria beat genetic ancestry at predicting heart and metabolic risk here, though it can't prove bacteria cause it.

A review of 143 studies on Lachnospiraceae, a gut bacteria family that turns fiber into immune-signaling fatty acids, found its strongest effects are from mice. The best human evidence comes from 158 cancer patients, where more of one Lachnospiraceae type tracked with more tumor-fighting immune cells in people who responded to checkpoint immunotherapy. That is correlation, not proof the bacteria caused it, and the human data overall stays thin.

TL;DR: Gut bacteria called Lachnospiraceae show a real but unproven link to how well cancer immunotherapy works, with almost all solid evidence still coming from mice, not people.